ILX-295501

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameILX-295501
Drug Alias NameLY-295501ILX-295501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsNeoplasm MetastasisFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyGenzyme Corp
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeN/A
Related LinksN/A